| Hovik Taymoorian, DO, PA | |
|
8028 Ritchie Hwy, Suite 126, Pasadena, MD 21122-1075 | |
| (410) 768-6702 | |
| (410) 768-6704 |
| Full Name | Hovik Taymoorian |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 30 Years |
| Location | 8028 Ritchie Hwy, Pasadena, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790749679 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | H0054974 (Maryland) | Primary |
| Entity Name | Hovik Taymoorian Do Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639349319 PECOS PAC ID: 6709056591 Enrollment ID: O20110906000319 |
News Archive
Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and the University of Illinois at Chicago today announce the publication of a study in Molecular Cell on the mechanism of action of odilorhabdins, a new class of antibiotics to combat antibiotic resistance.
Early signs show that, after years of decline, the number of small businesses offering coverage to employees is increasing. Perhaps less widely recognized, but no less significant, has been the way the law is demanding transparency and accountability from the insurance industry to bring down premiums.
Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.
In a recent review published in the journal, Advanced Functional Materials, researchers K. P. A. Kumar and Martin Pumera focused on the contributions of 3D printing technology towards the health sector in the wake of this deadly pandemic.
› Verified 6 days ago
| Entity Name | Medstar Medical Group Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000347 |
News Archive
Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and the University of Illinois at Chicago today announce the publication of a study in Molecular Cell on the mechanism of action of odilorhabdins, a new class of antibiotics to combat antibiotic resistance.
Early signs show that, after years of decline, the number of small businesses offering coverage to employees is increasing. Perhaps less widely recognized, but no less significant, has been the way the law is demanding transparency and accountability from the insurance industry to bring down premiums.
Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.
In a recent review published in the journal, Advanced Functional Materials, researchers K. P. A. Kumar and Martin Pumera focused on the contributions of 3D printing technology towards the health sector in the wake of this deadly pandemic.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hovik Taymoorian, DO, PA 8028 Ritchie Hwy, Suite 126, Pasadena, MD 21122-1075 Ph: (410) 768-6702 | Hovik Taymoorian, DO, PA 8028 Ritchie Hwy, Suite 126, Pasadena, MD 21122-1075 Ph: (410) 768-6702 |
News Archive
Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and the University of Illinois at Chicago today announce the publication of a study in Molecular Cell on the mechanism of action of odilorhabdins, a new class of antibiotics to combat antibiotic resistance.
Early signs show that, after years of decline, the number of small businesses offering coverage to employees is increasing. Perhaps less widely recognized, but no less significant, has been the way the law is demanding transparency and accountability from the insurance industry to bring down premiums.
Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.
In a recent review published in the journal, Advanced Functional Materials, researchers K. P. A. Kumar and Martin Pumera focused on the contributions of 3D printing technology towards the health sector in the wake of this deadly pandemic.
› Verified 6 days ago
Dr. Alicia Wasserman Sussman, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 8028 Ritchie Hwy Ste 134, Kaiser Permanente Severna Park Medical Center, Pasadena, MD 21122 Phone: 410-553-2400 | |
Dr. Valerie Anne Jones, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 8028 Ritchie Hwy, Pasadena, MD 21122 Phone: 410-553-4200 | |
Dana M Lee, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4231 Postal Ct, Ste 102, Pasadena, MD 21122 Phone: 410-553-8260 Fax: 410-787-4846 | |
Dr. Myrna Malan Ortega, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 8028 Ritchie Hwy Ste 309, Pasadena, MD 21122 Phone: 410-787-7000 |